Abstract:Aims: Myocardial cell replacement therapies are hampered by a paucity of sources for human cardiomyocytes and by the expected immune rejection of allogeneic cell grafts. The ability to derive patient-specific human-induced pluripotent stem cells (hiPSCs) may provide a solution to these challenges. We aimed to derive hiPSCs from heart failure (HF) patients, to induce their cardiomyocyte differentiation, to characterize the generated hiPSC-derived cardiomyocytes (hiPSC-CMs), and to evaluate their ability to integrate with pre-existing cardiac tissue. Methods and results: Dermal fibroblasts from two HF patients were reprogrammed by retroviral delivery of Oct4, Sox2, and Klf4 or by using an excisable polycistronic lentiviral vector. The resulting HF-hiPSCs displayed adequate reprogramming properties and could be induced to differentiate into cardiomyocytes with the same efficiency as control hiPSCs (derived from human foreskin fibroblasts). Gene expression and immunostaining studies confirmed the cardiomyocyte phenotype of the differentiating HF-hiPSC-CMs. Multi-electrode array recordings revealed the development of a functional cardiac syncytium and adequate chronotropic responses to adrenergic and cholinergic stimulation. Next, functional integration and synchronized electrical activities were demonstrated between hiPSC-CMs and neonatal rat cardiomyocytes in co-culture studies. Finally, in vivo transplantation studies in the rat heart revealed the ability of the HF-hiPSC-CMs to engraft, survive, and structurally integrate with host cardiomyocytes. Conclusions: Human-induced pluripotent stem cells can be established from patients with advanced heart failure and coaxed to differentiate into cardiomyocytes, which can integrate with host cardiac tissue. This novel source for patient-specific heart cells may bring a unique value to the emerging field of cardiac regenerative medicine.

Generation of high-performance human cardiomyocytes and engineered heart tissues from extended pluripotent stem cells

Engineering Human Ventricular Heart Muscles Based on a Highly Efficient System for Purification of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes

Comments about Possible Use of Human Embryonic Stem Cell-Derived Cardiomyocytes to Direct Autologous Adult Stem Cells into the Cardiomyogenic Lineage

Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells

Versatile human cardiac tissues engineered with perfusable heart extracellular microenvironment for biomedical applications

Generation of Highly Purified Human Cardiomyocytes from Peripheral Blood Mononuclear Cell-Derived Induced Pluripotent Stem Cells

Functional Engineered Human Cardiac Patches Prepared from Nature's Platform Improve Heart Function after Acute Myocardial Infarction.

Methods for the derivation and use of cardiomyocytes from human pluripotent stem cells

Generating Self-Assembling Human Heart Organoids Derived from Pluripotent Stem Cells

Advances in the Generation of Constructed Cardiac Tissue Derived from Induced Pluripotent Stem Cells for Disease Modeling and Therapeutic Discovery

Single-cell RNA sequencing reveals maturation trajectory in human pluripotent stem cell-derived cardiomyocytes in engineered tissues

Human Pluripotent Stem Cell-Derived Cardiac Cells: Application in Disease Modeling, Cell Therapy, and Drug Discovery

Engineered Maturation Approaches of Human Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes

Unveiling New Horizons in Heart Research: the Promise of Multi-Chamber Cardiac Organoids

Generation of Human Hepatocytes from Extended Pluripotent Stem Cells

Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest

Engineering a conduction-consistent cardiac patch with rGO/PLCL electrospun nanofibrous membranes and human iPSC-derived cardiomyocytes

Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors

Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients

Generation of a human iPSC-derived cardiomyocyte/fibroblast engineered heart tissue model

Efficient and reproducible generation of human iPSC-derived cardiomyocytes using a stirred bioreactor